During the 28th Annual North American Cystic Fibrosis Conference (NACFC) on October 9-11, clinical stage biotechnology company GlycoMimetics Inc will be presenting preclinical updates on GMI-1051, one of their leading candidates indicated for the treatment and prevention of Pseudomonas aeruginosa infections. The event will take place in the Georgia World Congress Center in Atlanta.

The poster presentation will revolve around GMI-1051?s ability to treat this bacterial infection, and will showcase the findings of several previously completed studies that sought to determine the drug’s amplifying effect on other antibacterial treatments.

GMI-1051 is formulated to target specific virulence factors that determine the bacteria’s growth and resistance, and in studies that involved animal models, was able to enhance the host body’s immunity, clearance of the pathogen, and odds of survival compared to being treated solely with antibiotics.